Therefore, it appears to be likely that the effect of enhanced chemerin production on FGF23 in CKD is overridden by various other stimulating effects on FGF23 associated with CKD, e.g. phosphate overload, inflammation, hyperparathyroidism. This evidence concerns the gene RARRES2 and hyperparathyroidism.